Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer

BACKGROUND: ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemotherapy in advanced breast cancer patients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Bos, M. K., Lam, S. W., Motta, G., Helmijr, J. C. A., Beaufort, C. M., de Jonge, E., Martens, J. W. M., Boven, E., Jansen, M. P. H. M., Jager, A., Sleijfer, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Laboratory Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241671/
https://www.ncbi.nlm.nih.gov/pubmed/37226020
http://dx.doi.org/10.1007/s10549-023-06965-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241671/
https://www.ncbi.nlm.nih.gov/pubmed/37226020
http://dx.doi.org/10.1007/s10549-023-06965-5

Ejemplares similares